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INTRODUCTION
Debates on the issue of infertility ended on Novem-
ber 30 2009, when the World Health Organization
(WHO) stated that infertility is a disease of the re-
productive system and defined as failure of preg-
nancy after 12 months or more of sexual inter-
course without contraception.1,2 It occurs at around
10-15% of reproductive age couples in the United
States, 5.4% in Europe, 3% in the Middle East,
10.1% in Africa, as well as 4.8% in Asia and
Oceania.3,4 Forty to fifty percent of infertility is
caused by abnormalities in women with ovulation
disorders in most cases (30-40%).5,6
Abstract
Objective: To compare the effects of ovulation induction with 2.5
mg letrozole to 5 mg letrozole by the number of mature follicles, en-
dometrial morphology and endometrium thickness during the late
follicular phase in infertility patient who successfully became preg-
nant.
Method: This was a cross sectional study. We collected the data of
infertility patient who successfully became pregnant after receiving
ovulation induction regiment of 2.5 mg and 5 mg letrozole.
Result: There mean number of follicles with diameter ≥ 18 mm was
higher in group receiving 5 mg letrozole (1.64 SD ± 0.91) compared
to group receiving 2.5 mg letrozole (1.37 SD ± 0.56) but statistically,
there was no significant difference (p = 0.134). Endometrial thick-
ness, which was measured by transvaginal ultrasound on the twelfth
day of menstrual cycle, showed a significant difference (p = 0.023)
between the groups. The endometrium was thicker in patients re-
ceiving 2.5 mg letrozole (7.83 mm SD ± 0.87) compared to patients
receiving 5 mg letrozole (7.6 mm SD ± 1.10). The most common en-
dometrium morphology found was triple line endometrium, both in
group receiving 2.5 mg letrozole (65%) and in group receiving 5 mg
letrozole (50%).
Conclusion: There was a significant difference in endometrial thick-
ness between the pregnant patients who had received 5 mg of letro-
zole and 2.5 mg of letrozole for ovulation induction and the most
common endometrium morphology and description was triple line
endometrium in both research groups. But there was no significant
difference between the number of ≥ 18 mm follicles on 2.5 mg doses
and 5 mg doses of letrozole.
[Indones J Obstet Gynecol 2012; 36-3: 130-4]
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Abstrak
Tujuan: Mengetahui efek induksi ovulasi dengan letrozole dosis 2,5
mg dibandingkan dengan dosis 5 mg terhadap jumlah folikel matur,
morfologi endometrium dan tebal endometrium pada fase folikular
akhir pada pasien infertilitas yang berhasil hamil.
Metode: Penelitian ini menggunakan desain penelitian potong lin-
tang. Data kasus-kasus pasien infertilitas yang berhasil hamil dengan
menggunakan terapi induksi ovulasi letrozole 2,5 mg dan 5 mg di-
kumpulkan dan dianalisis.
Hasil: Jumlah folikel dengan diameter ≥ 18 mm lebih banyak didapat-
kan pada dosis pemberian letrozole 5 mg (1,64 SD ± 0,91) diban-
dingkan dengan dosis pemberian letrozole 2,5 mg (1,37 SD ± 0,56)
walaupun secara statistik tidak menunjukkan perbedaan secara ber-
makna (p = 0,134). Ketebalan endometrium yang diukur dengan ul-
trasonografi transvaginal pada hari kedua belas siklus menstruasi
menunjukkan perbedaan secara bermakna (p = 0,023) di mana en-
dometrium didapatkan lebih tebal pada pemberian dosis letrozole 2,5
mg (7,83 mm SD ± 0,87) dibandingkan dengan pemberian letrozole 5
mg (7,6 mm SD ± 1,10). Didapatkan morfologi endometrium yang pa-
ling sering ditemui adalah trilaminer di kedua kelompok penelitian
yaitu 65% (letrozole 2,5 mg) dan 50% (letrozole 5 mg).
Kesimpulan: Induksi ovulasi pada pasien infertilitas yang mendapat
letrozole dan berhasil hamil memberikan perbedaan bermakna dalam
hal ketebalan endometrium antara kelompok dosis letrozole 2,5 mg
dan letrozole 5 mg. Tidak terdapat perbedaan bermakna antara jum-
lah folikel dengan diameter ≥ 18 mm pada kelompok letrozole 2,5 mg
dan letrozole 5 mg dan morfologi endometrium terbanyak adalah
gambaran trilaminer pada kedua kelompok dosis letrozole ini.
[Maj Obstet Ginekol Indones 2012; 36-3: 130-4]
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Ovulation induction is one of the most important
components in the management of ovulation dis-
orders.7,8 Clomiphene citrate (CC), an anti-estroge-
nic drug, is the first line of drug used in ovulation
induction. Occurrence of ovulation in patients who
received CC is ranged in about 80%. However, the
pregnancy rate is only 25-40%,9 and 10-30% of pa-
tients still experience anovulation even though
they already had the maximum dose of clomiphene
citrate. This condition is known as clomiphene cit-
rate resistance. Aromatase Inhibitor (AI) is an al-
ternative drug for ovulation induction that can be
used in this circumstances.10
Aromatase inhibitor is one of the anti-estrogenic
drug that is easy to use, relatively inexpensive, and
have little side effects.11 Letrozole (4.40-1 h -1,2.4-
triazol-1ylmethylene-bis-benzonitrile) is a third ge-
neration of AI that inhibits the production of estra-
diol by declining the conversion rate of testoste-
rone and androstenedion, thereby eliminating the
negative feedback on the hypothalamus and pitui-
tary gland of estradiol production.
Letrozole may be started until the third to se-
venth day of the menstrual cycle and cause the
growth of single follicles because of the short half-
time.12,13 The optimal dose of letrozole dose for in-
duction of ovulation until now has not yet been de-
termined. Many studies reported using 2.5-7.5
mg/day of letrozole. Al-Fadhli et al compared the
regiment of 2.5 mg doses and 5 mg letrozole, and
found that the average number of mature follicles
and the pregnancy rates were significantly higher
in patients receiving 5 mg letrozole. On the other
hand, higher dose of letrozole is associated with
more inhibition of aromatase activity, thus keeping
the levels of estradiol to be very low for adequate
endometrial growths when ovulation.15 It also had
effects on the cervical mucus. This hypothesis led
to the use of the 5 mg dose of letrozole for induction
ovulation is associated with lower pregnancy rates.
Due to the above problem this research was car-
ried out to assess the effect of ovulation induction
with letrozole 2.5 mg dose compared with doses of
5 mg by examining the number of mature follicles
and endometrial morphology in late follicular
phase.
METHOD
Secondary data was obtained from patient’s medi-
cal record. We collected data of infertility patients
who successfully became pregnant with letrozole
ovulation induction regime at the Moegni clinic,
Jakarta from January 2008 to December 2010. The
recapitulation, processing, and data analysis of this
study were conducted from January to December
2011.
There was an analytical observational studies
with cross-sectional design. We collected the data
of infertility patients who successfully became
pregnant after ovulation induction therapy with
2.5 mg and 5 mg letrozole. This data was used to
get an overview of the dominant follicle, the thick-
ness of the endometrium and endometrial mor-
phology on late follicular phase.
All research data was recorded in the research
form for the editing and coding process. Data was
then tabulated and processed statistically using
SPSS 17 for windows programs.
To see the characteristics of subjects, we con-
ducted univariate descriptive analysis. To examine
the relationship between infertility, the number of
cycles of ovulation induction, the age factor, the
amount of the dominant follicle, the thickness of
the endometrium and endometrial echogenicity af-
ter 12 days of ovulation induction in infertility pa-
tients with 2.5 mg and 5 mg letrozole, we con-
ducted an analysis with chi square test. If is not
qualify for chi square then it was analyzed with
Fisher test to obtain p value and confidence inter-
val value.
After obtaining the results of bivariate analysis,
the variables that have a significant relationship
with p<0.25 will be further analyzed with ad-
vanced multivariate analysis to find out which in-
dependent variable affects the success of the preg-
nancy. Logistic regression analysis was performed
to get the p value, the odd ratio and confidence
interval.
RESULTS
From the data of medical record, we retrieved 123
patients who successfully became pregnant with
letrozole regime. We finally obtained 88 subjects
who fulfilled the criteria of inclusion and exclusion.
 We gathered the results of anamnesis, physical
examination, the transvaginal ultrasonography ex-
amination (TVS), laboratory test, sperm analysis
and hysterosalphingografy (HSG).
The patient age was in the range of 21 to 43
years. Most of the subjects were in the age group
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30-35 years (48.8%). All subject at least had a high
school education, and 3.4% had graduated degree.
Among the subjects, 42% had normal BMI (18-25),
34% was categorized as overweight, while the re-
maining 24% was categorized as obese. All subjects
in this research had patent fallopian tube and nor-
mal sperm analysis result. The basic characteristics
of the subject can be seen in Table 1.





18-25 years  7  7.9
26-29 years 15 17  
30-35 years 43 48.8
36-40 years 19 22.5
> 40 years  4  4.5
 Education
High school 25 28.4
Diploma 30 34.1
Graduate 30 34.1
Postgraduate  3  3.4
 BMI
Underweight  0  0  
Normal 37 42  
Overweight 30 34  
Obesity 21 24  
Table 2 shows that the number of follicles with
diameter ≥ 18 mm obtained in 5 mg doses of le-
trozole (1.64 ± SD 0.91) compared with 2.5 mg
doses of letrozole (1.37 ± SD 0.56) and it showed
no significant difference (p = 0.134).
Endometrial thickness as measured by TVS on
day twelve of menstrual cycle showed a significant
difference (p = 0.023), in which the endometrium
was thicker in the group receiving 2.5 mg letrozole
(7.83 mm SD ± 0.87) compared to the group re-
ceiving 5 mg doses of letrozole (7.6 mm SD ± 1.10).
The result can be seen in Table 2.
For both group, endometrial morphology is also
assessed with TVS on day twelve of the menstrual
cycle. The result can be seen in Table 3.
The most commonly found morphology was the
triple line in both study groups, 65% of subjects in
group receiving 2.5 mg letrozole and 50% of sub-
jects in group receiving 5 mg letrozole. Hyperecho-
genic - homogenic morphology were obtained
more often in group receiving 5 mg letrozole
(5.6%) compared with he group receiving 2.5 mg
letrozole (1.9%). This difference is directly propor-
tional to the thickness of the endometrium, which
presented in most groups of 2.5 mg doses of letro-
zole.
From the aforementioned statistical test result,
it can be concluded that the number of follicles
with a diameter of ≥ 18 mm between the two
groups did not differ significantly (p = 0.134)
Table 2. Comparison of the number of follicles and endometrium thickness on day twelve of menstrual cycle after the regi-
ment of 2.5 mg and 5 mg letrozole.
Groups n Mean Std. Deviation p
Number offollicles with diameter ≥ 18 mm
2.5 mg 52 1.37  .56
0.134
5   mg 36 1.64  .91
Endometrium thickness (mm)
2.5 mg 52 7.831  .87
0.023
5   mg 36 7.600 1.10
Table 3. Endometrium morphology on day twelve of menstrual cycle after therapy of 2.5 mg and 5 mg letrozole.
Group
p2.5 mg 5 mg





Hyperechogenic - homogenic  1  1.9  2  5.6 0.281
Intermedia - Isoechogenic 17 32.6 16 44.4
Trilaminer 34 65  18 50  
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(means when p < 0.05), but the difference is sig-
nificant in terms of the thickness of the en-
dometrium (p = 0.023) between the two study
groups.
DISCUSSION
Letrozole, which was used as an ovulation induc-
tion regiment in this study, is one of the third gen-
eration aromatase inhibitor. It inhibits the produc-
tion of estrogen by decreasing the conversion rate
of testosterone and androstedione into estrogen in
the ovaries. Ovulation induction is one of the most
important components in the management ovula-
tion disorders.7,8
Letrozole as an aromatase inhibitor (AI) is an
anti-estrogen that is easy to use, relatively inex-
pensive, and has little side effect.11 The optimal
dose of letrozole for proper ovulation induction
has not been determined yet. From a few studies
showing the effectiveness of letrozole, some stud-
ies reported to use 2.5-7.5 mg letrozole per day.
There was no significant difference on the num-
ber of ≥ 18 mm follicle found in groups receiving
5 mg of letrozole (1.64 SD±0.91) compared to in
group receiving 2.5 mg letrozole (1.37 SD±0.56)
with p value of 0.134. On the study of Badawy14
and Al-Fadhli,15 they compared the result in pa-
tients receiving 2.5 mg and 5 mg letrozole, and they
found no significant difference in the number of
mature follicle between the groups. Success rate
per cycle using letrozole according to research con-
ducted by Badawy was higher in group receiving
2.5 mg letrozole (4.8%) compared to  group receiv-
ing 5 mg letrozole (4.3%), although the difference
was not statistically significant. On the other hand,
the study by Al-Fadhli15 obtained pregnancy rate
of 2.5% in group receiving 2.5 mg letrozole and
26.3% in group receiving 5 mg letrozole. It was as-
sociated with the average number of dominant fol-
licles, which was higher in the group receiving 5
mg letrozole. But, along with the growing number
of mature follicles, which was related to the doses
given, there was also an increase in the onset of
excessive ovarian stimulation syndrome caused by
rising levels of estradiol resulting from the large
number of mature follicles. Yet from the data col-
lected, there is no patient who experience exces-
sive ovarian stimulation syndrome.14 The level of
estradiol in mid luteal phase should be measured
in order to see if there is a significant difference
between the two groups in terms of its direct in-
fluence on the thickness of the endometrium and
its effects on the incidence of excessive ovarian
stimulation syndrome.
Endometrial thickness measured on day twelve
of menstrual cycle was significantly different (p =
0.023). This could be related to the theory which
stated that larger doses of letrozole are related to
an inhibition of aromatase enzyme activity that
makes the levels of estradiol too low to produce
growth of adequate endometrium.15 It also influ-
ences the condition of the cervical mucus. This hy-
pothesis led to the use of the 5 mg dose of letrozole
for induction ovulation is associated with lower
pregnancy rates. However, the research of Tulandi
et al showed different findings, where the thickness
of the endometrium is higher in value on a 5 mg
letrozole group (7.8 ± 0.3 mm) compared to 2.5 mg
(7.6 ± 0.3 mm), although in the end they conclude
a high success rate for pregnancy was not caused
by endometrial thickness, but the conditions of su-
perovulation where there were more dominant fol-
licles formed in groups receiving 5 mg letrozole. Al
Fadhli et al stated that the average number of ma-
ture (≥ 18 mm) follicles was significantly different
(p<0.005) between the two groups and the success
rate are directly proportional. The number of days
required to reach a mature follicle is associated
with increased doses of letrozole.15
Badawy14 also found that the endometrium in
the group receiving 5 mg letrozole was thinner
than in the group receiving 2.5 mg letrozole. Al-
Fadhli15 acquired a different result, where the en-
dometrial thickness was greater in the group re-
ceiving 5 mg letrozole (7.5 mm SD ± 0.3). In this
study, we found that the endometrium is signifi-
cantly thicker in group receiving 2.5 mg letrozole
(7.83 mm ± SD 0.87) than in group receiving 5 mg
letrozole (7.6 mm SD ± 1.10).
Previous studies stated that the differences in
the thickness of the endometrium did not affect the
success rate as long as endometrium thickness was
≥ 7 mm.
The examination of estradiol on day twelve cy-
cles of menstruation, just before the hormone hu-
man chorionic gonadotropin (hCG) injected to trig-
ger ovulation, should be performed. A study on es-
tradiol levels measured before hCG injection found
that that in the group with estradiol level of 1000-
2000 pg/ml, the rate of good quality embryos de-
velopment (73.6%) and high implantation and
pregnancy rates (35.8%) were higher compared to
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the group estradiol levels from 1000 to 2000
pg/ml.
 We would also like to see whether there was a
relationship between the number of dominant fol-
licle and endometrial thickness because there were
conflicting results from several researches regard-
ing this matter. Badawy et al found that the num-
ber of dominant follicles is proportional with in-
creased doses of letrozole. It was associated in-
creased progesterone levels in mid luteal phase,
thus the environment created in luteal phase was
better and the risk of abortion in patients who suc-
cessfully get pregnant decreased.14
Badawy et also stated that the changes in the
thickness of the endometrium was associated with
estradiol serum levels and an increase in the num-
ber of follicles. Another study stated that there was
a correlation between levels of serum estradiol
with endometrial thickness.
The number of pregnancy complications such as
abortion was also higher in group receiving 5 mg
letrozole (14.8%) compared to the group receiving
2.5 mg letrozole (12.1%).14
In this study, the most commonly found en-
dometrium morphology was the triple line en-
dometrium. A study suggested to delay embryo
transfer in in-vitro fertilization procedure when a
homogeneous hyperechoic pattern was found. A
triple line endometrium and endometrial thickness
of > 6 mm is associated with a high conception
rate.16
CONCLUSION
There was a significant difference in regards of en-
dometrial thickness between 2.5 mg and 5mg le-
trozole for ovulation induction. There was no sig-
nificant difference between the number of follicles
with diameter ≥ 18 mm on 2.5 mg doses and 5 mg
doses of letrozole and most endometrium mor-
phology and description are trilaminer in both re-
search groups.
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